Email updates

Keep up to date with the latest news and content from Journal of Cardiovascular MR and BioMed Central.

This article is part of the supplement: Abstracts of the 16th Annual SCMR Scientific Sessions

Open Access Poster presentation

Prognosis of anomalous coronary arteries originating from the opposite sinus of Valsalva (ACAOS): 15 year experience from two large CMR centres

David P Ripley12*, Albert Teis3, Akhlaque Uddin12, Petra Bijsterveld1, Ansuman Saha1, Ananth Kidambi12, Bernhard A Herzog12, Sven Plein12, Dudley J Pennell3 and John P Greenwood12

  • * Corresponding author: David P Ripley

Author Affiliations

1 Multidisciplinary Cardiovascular Research Centre (MCRC) & Leeds Institute of Genetics, Health and Therapeutics, University of Leeds, Leeds, UK

2 Leeds General Infirmary, Leeds Teaching Hospitals NHS Trust, Leeds, UK

3 Cardiovascular Magnetic Resonance Unit, Royal Brompton Hospital, London, UK

For all author emails, please log on.

Journal of Cardiovascular Magnetic Resonance 2013, 15(Suppl 1):P257  doi:10.1186/1532-429X-15-S1-P257

The electronic version of this article is the complete one and can be found online at:

Published:30 January 2013

© 2013 Ripley et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Aberrant coronary arteries represent a diverse group of congenital disorders, many of which may have no clinical significance. Post mortem studies show a high risk of exercise related sudden cardiac death in those with an anomalous coronary artery originating from the opposite sinus of Valsalva (ACAOS) that takes an inter-arterial (anterior) course. However, there is little documentation in life of the long term natural history of anomalous coronary arteries.


Databases from two cardiovascular magnetic resonance (CMR) centres (Leeds General Infirmary and Royal Brompton Hospital) were reviewed. Patients with anomalous coronary arteries undergoing CMR over a 15 year period (1995 to 2009) were identified. Anomalous coronary arteries were classified according to their anatomy and course. Both the electronic and paper records of all patients were reviewed for major adverse cardiovascular events (MACE) defined as cardiovascular mortality, myocardial infarction, revascularisation (PCI or CABG). Cause of death was verified by the Office for National Statistics. Revascularisation or myocardial infarctions were only counted if they occurred in the distribution of the anomalous artery.


173 consecutive patients with coronary artery anomalies were retrospectively identified with a median age 54 years (range 1-85). The median follow-up time was 4.3 years (IQR 2.5 - 7.8) with a maximum of 15.6 years. Of the 173 patients, 117 had ACAOS of which 111 were alive, 5 deceased and 1 lost to follow-up. 65 patients (56%) had an inter-arterial course and 52 (44%) a posterior course. The distribution of coronary anomalies is detailed in Table 1.

Table 1. Classification of anomalous coronary arteries (n=173)

In those patients with ACAOS there were 59 MACE events (5 cardiovascular deaths, 6 PCI, 24 CABG and 24 had myocardial infarction). 48 MACE events occurred in ACAOS with an anterior course and 11 with a posterior course (p<0.0001) the statistical difference driven by surgical revascularisation and myocardial infarction (Table 2).

Table 2. Major Adverse Cardiovascular Events in patients with an anomalous coronary artery originating from the opposite sinus of Valsalva (ACAOS) (n=117)


We have demonstrated that in life, patients with an anomalous coronary artery originating from the opposite sinus of Valsalva taking an anterior course, have higher rates of both myocardial infarction and surgical revascularisation during long-term follow up, compared to those with a posterior course.


S.P is funded by a British Heart Foundation fellowship (Fs/10/62/28409) S.P. and J.P.G received an educational research grant from Philips Healthcare.